Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ninjin'yoeito for prevention of sarcopenia in advanced urothelial carcinoma patients receiving chemotherapy
jRCTs021210048Completed
- Sponsor
- Kracie
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ninjinyoeito in transitional cell carcinoma (TCC) and Sarcopenia, sponsored by Kracie. Primary endpoint: Change rate of psoas muscle area at 8 weeks versus historical cohort. Started Nov 2021; status: completed.
02
Drugs
ninjinyoeito
03
Conditions
transitional cell carcinoma (TCC)Sarcopenia
Beyond the preview
Go deeper on jRCTs021210048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210048.